{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:06:59Z","timestamp":1782176819822,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07839-w","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:23:20Z","timestamp":1774250600000},"page":"4905-4912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intraprostatic PSMA PET\/MRI parameters and clinical markers for ISUP prediction and postoperative biochemical recurrence in patients with primary prostate cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Holger","family":"Einspieler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"N\u00fcrnberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens P.","family":"Spielvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Nics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal A. T.","family":"Baltzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"Huebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Grubm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2898-3232","authenticated-orcid":false,"given":"Sazan","family":"Rasul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"7839_CR1","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","volume":"75","author":"T Van den Broeck","year":"2019","unstructured":"Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2019;75:967\u201387. https:\/\/doi.org\/10.1016\/j.eururo.2018.10.011.","journal-title":"Eur Urol"},{"key":"7839_CR2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","volume":"177","author":"MS Cookson","year":"2007","unstructured":"Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D\u2019Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540\u20135. https:\/\/doi.org\/10.1016\/j.juro.2006.10.097.","journal-title":"J Urol"},{"key":"7839_CR3","doi-asserted-by":"publisher","first-page":"e17112","DOI":"10.1200\/JCO.2023.41.16_suppl.e17112","volume":"41","author":"N Khan","year":"2023","unstructured":"Khan N, McKay RR, Spratt DE, Constantinovici N, Chen G, Ortiz JA, et al. Biochemical recurrence (BCR) and outcomes in patients (pts) with prostate cancer (PC) following radical prostatectomy (RP). JCO Wolters Kluwer. 2023;41:e17112\u201317112. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e17112.","journal-title":"JCO Wolters Kluwer"},{"key":"7839_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bju.14828","volume":"124","author":"JW Yaxley","year":"2019","unstructured":"Yaxley JW, Raveenthiran S, Nouhaud F-X, Samaratunga H, Yaxley WJ, Coughlin G, et al. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography\/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019;124:401\u20137. https:\/\/doi.org\/10.1111\/bju.14828.","journal-title":"BJU Int"},{"key":"7839_CR5","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81\u20135.","journal-title":"Clin Cancer Res"},{"key":"7839_CR6","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.3390\/cancers16244263","volume":"16","author":"F von Stauffenberg","year":"2024","unstructured":"von Stauffenberg F, Poyet C, Beintner-Skawran S, Maurer A, Schmid FA. Current Clinical Applications of PSMA-PET for Prostate Cancer Diagnosis, Staging, and Treatment. Cancers. Multidisciplinary Digit Publishing Inst. 2024;16:4263. https:\/\/doi.org\/10.3390\/cancers16244263.","journal-title":"Multidisciplinary Digit Publishing Inst"},{"key":"7839_CR7","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7.","journal-title":"Lancet"},{"key":"7839_CR8","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.3390\/diagnostics13142343","volume":"13","author":"KCC de Bie","year":"2023","unstructured":"de Bie KCC, Veerman H, Bodar YJL, Meijer D, van Leeuwen PJ, van der Poel HG, et al. Higher Preoperative Maximum Standardised Uptake Values (SUVmax) Are Associated with Higher Biochemical Recurrence Rates after Robot-Assisted Radical Prostatectomy for [68Ga]Ga-PSMA-11 and [18F]DCFPyL Positron Emission Tomography\/Computed Tomography. Diagnostics (Basel). 2023;13:2343. https:\/\/doi.org\/10.3390\/diagnostics13142343.","journal-title":"Diagnostics (Basel)"},{"key":"7839_CR9","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2967\/jnumed.119.233940","volume":"61","author":"O Martin","year":"2020","unstructured":"Martin O, Schaarschmidt BM, Kirchner J, Suntharalingam S, Grueneisen J, Demircioglu A, et al. PET\/MRI Versus PET\/CT for Whole-Body Staging: Results from a Single-Center Observational Study on 1,003 Sequential Examinations. J Nuclear Med Soc Nuclear Med. 2020;61:1131\u20136. https:\/\/doi.org\/10.2967\/jnumed.119.233940.","journal-title":"J Nuclear Med Soc Nuclear Med"},{"key":"7839_CR10","doi-asserted-by":"publisher","first-page":"20210728","DOI":"10.1259\/bjr.20210728","volume":"95","author":"F-Y Liu","year":"2022","unstructured":"Liu F-Y, Sheng T-W, Tseng J-R, Yu K-J, Tsui K-H, Pang S-T, et al. Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET\u2013CT vs PET\u2013MRI. Br J Radiol. 2022;95:20210728. https:\/\/doi.org\/10.1259\/bjr.20210728.","journal-title":"Br J Radiol"},{"key":"7839_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/j.semnuclmed.2023.08.001","volume":"54","author":"MCM Gammel","year":"2024","unstructured":"Gammel MCM, Solari EL, Eiber M, Rauscher I, Nekolla SG. A Clinical Role of PET-MRI in Prostate Cancer? Semin Nucl Med. 2024;54:132\u201340. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.08.001.","journal-title":"Semin Nucl Med"},{"key":"7839_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00259-023-06392-0","volume":"51","author":"F Gossili","year":"2023","unstructured":"Gossili F, Mogensen AW, Konnerup TC, Bouchelouche K, Alberts I, Afshar-Oromieh A, et al. The diagnostic accuracy of radiolabeled PSMA-ligand PET for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2023;51:281\u201394. https:\/\/doi.org\/10.1007\/s00259-023-06392-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7839_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.euo.2023.08.002","volume":"7","author":"S Wang","year":"2024","unstructured":"Wang S, Kozarek J, Russell R, Drescher M, Khan A, Kundra V, et al. Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2024;7:189\u2013203. https:\/\/doi.org\/10.1016\/j.euo.2023.08.002.","journal-title":"Eur Urol Oncol"},{"key":"7839_CR14","doi-asserted-by":"publisher","first-page":"20015","DOI":"10.1038\/s41598-020-76786-9","volume":"10","author":"I Yusim","year":"2020","unstructured":"Yusim I, Krenawi M, Mazor E, Novack V, Mabjeesh NJ. The use of prostate specific antigen density to predict clinically significant prostate cancer. Sci Rep Nat Publishing Group. 2020;10:20015. https:\/\/doi.org\/10.1038\/s41598-020-76786-9.","journal-title":"Sci Rep Nat Publishing Group"},{"key":"7839_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2967\/jnumed.122.264981","volume":"64","author":"Val Jalali","year":"2023","unstructured":"Jalali Val, Wasinger G, Rasul S, Grubm\u00fcller B, Wulkersdorfer B, Balber T, et al. Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Na\u00efve Prostate Cancer. J Nuclear Med Soc Nuclear Med. 2023;64:863\u20138. https:\/\/doi.org\/10.2967\/jnumed.122.264981.","journal-title":"J Nuclear Med Soc Nuclear Med"},{"key":"7839_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrc2351","volume":"8","author":"H Lilja","year":"2008","unstructured":"Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer Nat Publishing Group. 2008;8:268\u201378. https:\/\/doi.org\/10.1038\/nrc2351.","journal-title":"Nat Rev Cancer Nat Publishing Group"},{"key":"7839_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2967\/jnumed.117.195172","volume":"59","author":"N Woythal","year":"2018","unstructured":"Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen J-C, Huang K, et al. Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET\/CT in Primary Prostate Cancer. J Nucl Med. 2018;59:238\u201343. https:\/\/doi.org\/10.2967\/jnumed.117.195172.","journal-title":"J Nucl Med"},{"key":"7839_CR18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. 68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44:941\u20139. https:\/\/doi.org\/10.1007\/s00259-017-3631-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7839_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/MNM.0000000000000942","volume":"40","author":"E Demirci","year":"2019","unstructured":"Demirci E, Kabasakal L, \u015eahin OE, Akg\u00fcn E, G\u00fcltekin MH, Do\u011fanca T, et al. Can SUVmax values of Ga-68-PSMA PET\/CT scan predict the clinically significant prostate cancer? Nucl Med Commun. 2019;40:86\u201391. https:\/\/doi.org\/10.1097\/MNM.0000000000000942.","journal-title":"Nucl Med Commun"},{"key":"7839_CR20","doi-asserted-by":"publisher","first-page":"8396","DOI":"10.7150\/thno.58140","volume":"11","author":"J Jiao","year":"2021","unstructured":"Jiao J, Kang F, Zhang J, Quan Z, Wen W, Zhao X, et al. Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET\/CT: a real-world study. Theranostics. 2021;11:8396. https:\/\/doi.org\/10.7150\/thno.58140.","journal-title":"Theranostics"},{"key":"7839_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2967\/jnumed.113.123547","volume":"55","author":"KZ Al-Nabhani","year":"2014","unstructured":"Al-Nabhani KZ, Syed R, Michopoulou S, Alkalbani J, Afaq A, Panagiotidis E, et al. Qualitative and Quantitative Comparison of PET\/CT and PET\/MR Imaging in Clinical Practice. J Nuclear Med Soc Nuclear Med. 2014;55:88\u201394. https:\/\/doi.org\/10.2967\/jnumed.113.123547.","journal-title":"J Nuclear Med Soc Nuclear Med"},{"key":"7839_CR22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.prnil.2022.03.003","volume":"10","author":"Y Zeng","year":"2022","unstructured":"Zeng Y, Leng X, Liao H, Jiang G, Chen P. Diagnostic value of integrated 18F-PSMA-1007 PET\/MRI compared with that of biparametric MRI for the detection of prostate cancer. Prostate Int. 2022;10:108\u201316. https:\/\/doi.org\/10.1016\/j.prnil.2022.03.003.","journal-title":"Prostate Int"},{"key":"7839_CR23","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1002\/cam4.5516","volume":"12","author":"N Yi","year":"2023","unstructured":"Yi N, Wang Y, Zang S, Yang L, Liu H, Sun H, et al. Ability of 68 Ga-PSMA PET\/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate-risk prostate cancer: A single-center retrospective study of 147 patients. Cancer Med. 2023;12:7140\u20138. https:\/\/doi.org\/10.1002\/cam4.5516.","journal-title":"Cancer Med"},{"key":"7839_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2967\/jnmt.115.161745","volume":"43","author":"G Akamatsu","year":"2015","unstructured":"Akamatsu G, Ikari Y, Nishida H, Nishio T, Ohnishi A, Maebatake A, et al. Influence of Statistical Fluctuation on Reproducibility and Accuracy of SUVmax and SUVpeak: A Phantom Study. J Nuclear Med Technol Soc Nuclear Med. 2015;43:222\u20136. https:\/\/doi.org\/10.2967\/jnmt.115.161745.","journal-title":"J Nuclear Med Technol Soc Nuclear Med"},{"key":"7839_CR25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s12885-024-12029-8","volume":"24","author":"F Cui","year":"2024","unstructured":"Cui F, Qiu Y, Xu W, Zou C, Fan Y. Pretreatment prostate-specific antigen density as a predictor of biochemical recurrence in patients with prostate cancer: a meta-analysis. BMC Cancer. 2024;24:305. https:\/\/doi.org\/10.1186\/s12885-024-12029-8.","journal-title":"BMC Cancer"},{"key":"7839_CR26","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1259\/bjr.71.848.9828800","volume":"71","author":"I Aref","year":"1998","unstructured":"Aref I, Eapen L, Agboola O, Cross P. Is prostate specific antigen density an important prognostic indicator for patients with prostate cancer treated with external beam therapy? Br J Radiol. 1998;71:868\u201371. https:\/\/doi.org\/10.1259\/bjr.71.848.9828800.","journal-title":"Br J Radiol"},{"key":"7839_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5173\/ceju.2023.187","volume":"77","author":"U Carbonara","year":"2024","unstructured":"Carbonara U, Adamou C, Darlington Carbin D, Papadopoulos D, Fragkoulis G, Whiting D, et al. Predictors of biochemical recurrence after robot-assisted radical prostatectomy: single-centre analysis. Cent Eur J Urol. 2024;77:189\u201395. https:\/\/doi.org\/10.5173\/ceju.2023.187.","journal-title":"Cent Eur J Urol"},{"key":"7839_CR28","doi-asserted-by":"publisher","unstructured":"Karpinski MJ, Hober\u00fcck S, Fendler WP, Civan C, Bundschuh RA, Thomas C et al. Association between the PRIMARY score at staging prostate-specific membrane antigen positron emission tomography and overall survival among patients with newly diagnosed prostate cancer: findings from the international, multicenter PROMISE registry. European Urology [Internet]. 2025 [cited 2025 Nov 12]; https:\/\/doi.org\/10.1016\/j.eururo.2025.10.013.","DOI":"10.1016\/j.eururo.2025.10.013"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07839-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07839-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07839-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:41:06Z","timestamp":1781642466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07839-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7839"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07839-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marcus Hacker is an editor at this journal. He was not involved in the peer-review or editorial decision-making for this manuscript. The remaining authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The retrospective study was approved by the Ethics Committee of the Medical University of Vienna (EK: 1745\/2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"All patients gave their written informed consent prior to the examinations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}